An open-label, single-dose, randomized, 3-period, crossover, bioequivalence study between two new formulations of 0.45mg/1.5mg Premarin [conjugated estrogens]/medroxyprogesterone acetate (MPA) compared with a reference formulation of 0.45mg/1.5mg Premarin/MPA (Prempro in healthy postmenopausal women
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2007
At a glance
- Drugs Conjugated estrogens/medroxyprogesterone (Primary)
- Indications Menopausal syndrome
- Focus Pharmacokinetics
- Sponsors Wyeth
- 08 Jun 2007 Status change from, initiated to completed (according to NCT).
- 16 Oct 2006 New trial record.